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Women with peripheral artery disease are at lower risk for cardiovascular events. 
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Background: Patients with peripheral artery disease (PAD) have a higher risk of major 
adverse cardiovascular events (MACE) as compared with those without PAD. 
Objective: The aim of this post hoc analysis was to evaluate sex-specific differences in 
MACE and limb events in the EUCLID (Examining Use of tiCagreLor In paD) trial.  
Methods: Cox proportional hazards models were used to compare time-to-event outcomes 
stratified by sex. Covariates were introduced after adjusted model selection.  
Results: EUCLID enrolled 13,885 patients with PAD (28% women [n=3888]). PAD severity 
and medical treatment were comparable between sexes, whereas prior lower extremity 
revascularization was reported less frequently in women (54.8% vs 57.3%; p=0.006). Women 
were older (mean ± standard deviation [SD] 67.88.9 vs 66.18.2 years;p<0.001) and more 
likely to have diabetes mellitus (p=0.004), hypertension, hyperlipidemia, and chronic kidney 
disease (all p<0.001). Over a mean follow-up of 30 months, women had a lower risk of 
MACE (9.5% vs 11.2%; adjusted hazard ratio [aHR] 0.77; 95% confidence interval [CI] 
0.68–0.88, p<0.001) and all-cause-mortality (7.6% vs 9.7%; aHR 0.61; 95% CI 0.53–0.71, 
p<0.001). In contrast, risk for major adverse limb events (2.6% vs 3.0%) and hospitalization 
for acute limb ischemia (1.6% vs 1.7%) were not different by sex.  
Conclusions: While women with PAD are at lower risk for MACE and all-cause mortality, 
risk for limb events was similar between sexes over a mean follow-up of 30 months. 
Understanding sex-specific differences as well as dissociation between baseline 
cardiovascular risk and subsequent cardiovascular events require further investigation.  
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Patients with peripheral artery disease (PAD) have a higher risk of major adverse 
cardiovascular events (MACE) as compared with those without PAD. We evaluate sex-
specific differences in MACE and limb events in the EUCLID trial. Cox proportional hazards 
models were used to compare time-to-event outcomes stratified by sex. Covariates were 
introduced after adjusted model selection. While women with PAD were at lower risk for 
MACE and all-cause mortality, risk for limb events was similar between sexes over a mean 
follow-up of 30 months. Understanding sex-specific differences dissociation between baseline 




ALI=acute limb ischemia 
CI=confidence interval 
EUCLID=Examining Use of tiCagreLor In paD trial 
aHR=adjusted hazard ratio 
LER=lower extremity revascularization 
MACE=major adverse cardiovascular and cerebrovascular events 
MALE=major adverse limb events 
PAD=peripheral artery disease 




Lower extremity peripheral artery disease (PAD) is an important global health problem 
progressively affecting millions of people worldwide (1). Population-based trends and studies 
suggest that women are affected at least as often as men, and a recent meta-analysis 
confirmed a comparable PAD prevalence for both sexes, defined as an ankle brachial index 
(ABI) ≤0.90 (2).  
Nevertheless, while it is recognized that patients with established PAD have a significantly 
greater risk of major adverse cardiovascular events (MACE), defined as myocardial infarction 
(MI), stroke, and cardiovascular death, as compared with patients without PAD (3-7), sex-
specific differences have not been well defined (8). Evidence of a PAD-related increase in 
disability and mortality in women is limited, as the overall number of women included in 
population-based analyses are comparably low and prone to selection bias (5,9). Women are 
underrepresented in clinical trials (10), which may be partially related to differences in the 
nature and timing of clinical manifestations of atherosclerosis in women. Moreover, PAD 
analyses have focused on lower extremity revascularization (LER) outcomes that 
predominantly are based on non-randomized cohorts and regional and national databases with 
conflicting findings in the short- and long-term period (11). 
To address the gap in knowledge, this post hoc analysis of the global EUCLID trial 
(Examining Use of tiCagreLor In paD) compares sex-related differences and cardiovascular 
events including limb ischemic outcomes in a comtemporary, large cohort of male and female 
patients with established PAD.  
 
METHODS 
Design and results of the EUCLID trial (NCT01732822) have been published previously (12). 
Briefly, EUCLID was an international, multicenter, double-blind trial that evaluated treatment 
with ticagrelor 90 mg twice daily or clopidogrel 75 mg daily in 13,885 patients with stable 
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PAD. Eligible patients were ≥50 years of age with lower extremity PAD. Patients were 
enrolled who were symptomatic with an abnormal ankle-brachial index (ABI) ≤0.80 at 
screening (n=6010) or a prior LER more than 30 days before randomization (n=7875). Key 
exclusion criteria included planned use of dual antiplatelet therapy or use of aspirin, high risk 
of bleeding, treatment with anticoagulation, poor metabolizer status for CYP2C19, planned 
revascularization (any territory), or major amputation within 3 months. All patients provided 
written informed consent and institutional review boards approved the protocol at 
participating institutions. The overall results of the trial did not support superiority of 
ticagrelor over clopidogrel for the primary endpoint of a composite of cardiovascular death, 
MI, or ischemic stroke, including sex-specific subgroup analysis (13).  
 
Sex-specific outcomes 
The present post hoc analysis focuses on sex-related disparities in the EUCLID trial with a 
view on PAD status, cardiovascular risk factor profile, treatment, and cardiovascular 
outcomes. In EUCLID, data on occurrence of the primary endpoint (MACE, a composite of 
cardiovascular death, MI, or ischemic stroke), all-cause mortality, hospitalization for acute 
limb ischemia (ALI), major amputation, subsequent LER procedures, and Thrombolysis in 
Myocardial Infarction (TIMI) major bleeding events were systematically reported according 
to the trial design. Major adverse limb events (MALE) were defined as the first occurance of 
ALI or major amputation. ALI defined as a hospitalization involving a rapid or sudden 
decrease in limb perfusion and either a new pulse deficit, rest pain, pallor, paresthesia, 
paralysis or objective confirmation of arterial obstruction. MALE plus postrandomization 
LER was defined as a three component outcome measure including ALI requiring 
hospitalization, post-randomization LER without fulfilling the criteria of ALI, and major 
amputation. Endpoints including MALE were adjudicated by a clinical events classification 




Statistical analysis  
All patients in EUCLID (n=13,885) were grouped according to sex. Categorical variables are 
presented as counts (%) and continuous variables are presented as means, standard deviations 
(SD), medians, 25th percentiles, 75th percentiles, and the number of participants with non-
missing data. The differences in baseline characteristics were analyzed using a 2-sample t-test 
for continuous variables (age, weight, cholesterol, hemoglobin A1C, estimated glomerular 
filtration rate [eGFR]), and by a chi-square test (all cell sizes ≥5) or Fisher’s exact test (at 
least 1 cell size <5) for categorical variables. Baseline characteristics were summarized by sex 
for the full population. A backward elimination model selection procedure provided the basis 
for selecting the covariates to include in the adjusted analysis of each event type. The starting 
models considered the following covariates: sex, age, weight, tobacco use, region, number of 
vascular beds, Rutherford classification, history of various medical conditions (major or 
minor amputations; stroke, TIA, carotid stenosis, or carotid revascularization; myocardial 
infarction, coronary artery disease, percutaneous coronary intervention, or coronary artery 
bypass graft; diabetes; hypertension; hyperlipidemia; prior revascularization; chronic kidney 
disease), and use of various medications prior to randomization (aspirin; clopidogrel; dual 
antiplatelet therapy; statins; ACE and/or ARB inhibitors). The covariates considered for 
model building were consistent with the covariates considered for other post-hoc analyses of 
the EUCLID trial conducted to date. The criteria for selection in the adjusted model for each 
outcome was p<0.05; sex was retained in the adjusted models, regardless of whether it met 
the significance threshold of p<0.05 or not. Cox proportional hazards models were used to 
compare the time-to-event outcomes. Data were censored for patients in whom the event in 
question had not occurred at either the censoring date for the primary analysis or the last trial 
contact when all components of the endpoint in question were assessed, whichever came first. 
Estimates of the event rate per 100 patient-years (pt-ys) were calculated for each event type 
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using the following equation: [(number of persons with event) / (sum of time at risk for event 
for all persons/360)]*100. Kaplan-Meier estimates of the (unadjusted) cumulative proportion 
of patients for each event were presented by sex. An analysis was conducted to explore the 
interaction between age group (<65 years, ≥65 years) and sex for MACE and MALE events. 
The p-values and 95% confidence intervals (CI) for the HRs are reported; p-values and CIs 
for the HRs are based on the Wald statistic. The statistical testing was not controlled for 
multiplicity and therefore all p-values reported should be interpreted as descriptive, nominal 
statistics. All statistical analyses were performed per CPC Standard Operating Procedures 




Demographic and baseline characteristics 
Demographics and baseline characteristics are shown in Table 1. A total of 3888 (28%) 
female patients were enrolled in the EUCLID trial. There were no sex-related differences in 
PAD severity defined according to the Rutherford classification. However, women had fewer 
prior LER procedures as compared with men (54.8% vs. 57.3%, p=0.006). Female patients 
with prior LER were more likely to have prior endovascular revascularization as compared 
with men (72.0% vs. 65.0%, p<0.001), with less common iliac vessel treatment (30.6% vs. 
34.0%) and a higher portion of femoropopliteal artery disease being treated (48.4% vs. 
42.8%). In accordance with the anatomical distribution pattern of endovascular treatment, 
female patients underwent more femoropopliteal bypass above the knee, whereas male 
patients more often had aorto-bifemoral bypass or femoropopliteal bypass below the knee 
(Table 2). Medication including antiplatelet therapy, statins, angiotensin converting enzyme 
inhibitors and/or angiotensin-receptor blockers for secondary prevention was not different 
between female and male patients at baseline. Overall, women were significantly older and 
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were more likely to have diabetes mellitus, hypertension, hyperlipidemia, and chronic kidney 
disease than men. In contrast, women were less likely to be current or former smokers, and 
less frequently had a history of cerebrovascular events/revascularizations, coronary 
events/revascularizations, or established polyvascular disease. 
 
Event rates and outcome  
Over a mean follow-up of 30 months, women had a significant lower risk of MACE (9.5% vs 
11.2%; adjusted HR [aHR] 0.77; 95% CI 0.68-0.88, p<0.001) and all-cause-mortality than 
men (7.6% vs 9.7%; aHR 0.61; 95% CI 0.53-0.71, p<0.001) (Table 3). Women also had a 
lower risk of cardiovascular death (4.3% vs 5.4%; aHR 0.65; 95% CI 0.54-0.78, p<0.001), 
and MI (4.5% vs 5.1%; aHR 0.79; 95% CI 0.66-0.95, p< 0.014), but the risk of ischemic 
stroke was not different between sexes (2.0% vs 2.2%). In contrast, there was no significant 
sex-specific difference in MALE (2.6% vs 3.0%) or post-randomization LER (12.6% vs 
12.5%) over the mean follow-up of 30 months (Table 3). Kaplan-Meier estimates by sex for 
MACE, all-cause mortality, MALE, and post-randomization LER are shown in Figure 1A-D. 
A subset of 1738 patients, including 491 women (28.2%), underwent post-randomization LER 
(Table S1). A higher proportion of women had an ALI event occurring after post-
randomization LER compared with men (6.7% vs 4.7%, Table S1). However, inclusion of 
post-randomization LER procedures as a time-dependent covariate had no meaningful impact 
on the risk of subsequent MACE and MALE events between sexes (Table S2).  
There was a trend for less bleeding in the female patients (TIMI major bleeding 1.4% vs 
1.7%; aHR 0.75; 95% CI 0.55–1.02; p=0.069), though none of the differences in bleeding 
events (i.e., TIMI major bleeding, intracranial bleeding, fatal bleeding) reached statistical 





Event rates by sex and outcome by age groups  
Overall, 5885 (42.4%) patients were <65 years of age with a higher proportion of males as 
compared with women (44.7% vs. 36.4%). While the HRs for females were lower in subjects 
< 65 and also lower for those ≥65 there was not statistical interaction by age and thus the risk 
differences for females was consistently lower across these younger and older age groups 
(Table 4). There was also no statistical interaction by age strata and sex for MALE. 
 
DISCUSSION 
This EUCLID post hoc analysis of 13,885 patients with PAD reveals several novel findings 
regarding sex-specific differences in cardiovascular disease that require further investigation. 
Women with established lower extremity PAD are at lower risk for MACE and all-cause 
mortality compared with their male counterparts, whereas their risk for MALE, defined as 
hospitalization for ALI or major amputation, is similar over a follow-up period of 30 months. 
Interestingly enough, there seems to be an obvious dissociation between risk factors present 
and clinical outcome. Although women are older and have a higher prevalence of diabetes 
mellitus, hypertension, and hyperlipidemia, they have a significant lower rate of MACE 
compared with men.  
Similar to other international PAD cohort studies, the EUCLID study population has a higher 
proportion of male participants, patients from North America and Europe, and those of white 
race (10,14,15). Numerous factors as age, socioeconomic status, and racial or ethnic 
affiliation affect participation in clinical trials. In particular, sex-based disparities are not 
limited to cardiovascular, but are found in cancer or other clinical trials and continue to be a 
challenge. Call to action campaigns have made some progress, but contemporary rates of 
female clinical trial participation continue to be about one third (16,17). 
A main strength of this large PAD-specific study population is the comparable severity of 
PAD and medical cardiovascular secondary prevention therapy between sexes. Moreover, 
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cardiovascular events were adjudicated by a clinical events classification group and less than 
2% of patients were lost to follow-up over a mean of 30 months.  
Despite comparable severity of lower extremity PAD, male patients had undergone more 
prior surgical procedures. This sex-specific difference matches data from the literature. 
Explanations given are differences in perceived physical distress between sexes and 
development of cardiovascular disease being delayed by about 10 years in women compared 
with men (11,18,19). Although the rate of prior LER procedures was higher in men by 
statistical means the absolute difference (2.5%) is not sufficient to assume that men enrolled 
in EUCLID have more severe PAD to explain differences on this basis. In contrast to the 
increased rate of events and polyvascular disease manifestation in men in EUCLID, the 
prevalence of cardiovascular risk factors is more pronounced in women. Moreover, in 
accordance with data from the REACH registry, women are significantly older (20). The sex-
specific dissociation of risk factors with MALE in a homogeneous PAD population suggests 
other genetic factors that either act independently or interact with the mode of action of the 
risk factor. Evidence on sex-specific cardiovascular event rates in PAD populations is poor or 
based on out-of-date data surveys (10). Sigvant et al. analyzed studies with at least 1 year of 
follow-up and found no risk difference by sex for cardiovascular mortality, but an increased 
risk for all-cause mortality by one-third in male patients with PAD (21). This is in accordance 
with a propensity score matched analysis of inpatients in Germany that identified male 
patients with PAD to be at risk for mortality during 4 years of follow-up (18). On the other 
hand and in contrast, 2 PAD cohort studies from Canada and the Netherlands found no sex 
difference for mortality (22,23). Based on conflicting results on outcomes by sex, a call to 
action review article by the Americican Heart Association was published underlining the need 
for more robust data and resulting consequences (8).  
It is generally accepted, and shown for the EUCLID population as well, that presence of 
polyvascular disease, when compared with patients with PAD alone, is associated with an 
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increased risk for MACE (24). Therefore, the more advanced manifestation of atherosclerosis 
in several arterial beds in men must be considered as a reason for sex-differences in MACE 
shown in this analysis. The reason for the more advanced disease in men with comparable 
severity of PAD, however, remains to be elucidated. In contrast to MACE, limb events are 
comparable between sexes in EUCLID over the follow-up period of 30 months. In a small 
subgroup of patients with post-randomization LER, the only difference is a slight increase in 
ALI in female patients. Egorova et al. compared inpatient data by sex that showed constantly 
higher rates of emergency PAD hospitalization in women over 10 years (25). Data from a US 
registry indicated a more frequent rate of LER for rest pain in women when compared with 
men (19). Factors discussed as reasons for a higher risk for ALI by sex consider that women 
were older when undergoing LER, they have more advanced disease, smaller arteries, and 
several differences regarding epidemiology and clinical presentation including awareness of 
PAD (8).  
Sex-specific differences between risk of MACE and prevalence of classical cardiovascular 
risk factors are described for non-PAD populations, but results are conflicting as populations 
studied vary. The historical Finnmark study showed that in women more than in men smoking 
was a stronger risk factor for MI  during 12 years of follow-up (26). Further epidemiological 
data from a general population pointed to an increased risk for women over men with regard 
to cardiovascular mortality and MI by smoking and diabetes (27,28). Two meta-analyses, 
each including more than 750,000 individuals, reported on a pronounced relative risk by 
female sex for fatal coronary heart disease and stroke in patients with diabetes mellitus 
(29,30). In contrast to classical cardiovascular risk factors, it is believed that estrogen has a 
protective effect on the vascular system and hormone receptor signalling may play a leading 
role for better understanding risk differences in the pathogenesis of atherosclerotic arterial 
disease influenced by age (31). The fact that its protective impact gets lost with menopause, 
and thereafter prevalence of vascular disease increases for women, underlines the robustness 
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of our data of a reduced risk difference by sex and older age group for MACE (32-
35). Nevertheless and in contrast, the Heart and Estrogen/progestin Replacement Study did 
not demonstrate a benefical effect of estrogen/progestin replacement to reduce risk of 
cardiovascular events in postmenopausal women with coronary heart disease (36). 
  
Limitations 
The EUCLID trial was not designed to specifically evaluate sex-related differences in the 
baseline characteristics or outcomes in PAD patients. Potential confounders in this post hoc 
analysis might include a selection bias for patients from high income countries and racial and 
ethnic differences (1,8,14,37-39). Black women, reported to have a disproportional high risk 
of cardiovascular events and poor limb specific outcome, were underrepresented and sex-
specific disparities might have additional racial causes (40).  Recently relations between 
ethnicity, socioeconomic status, gender and outcomes in PAD patients have been described 
(41). EUCLID enrolled African American patients and patients from low income countries, 
however, numbers were small and selection bias likely. Nevertheless, an influence by 
ethnicity on sex-specific differences found in the EUCLID post hoc analysis cannot be 
excluded (41). Disparities in cardiovascular risk factors were limited to prevalence without 
information on the cumulative effect as smoking pack years, duration of diabetes, or control 
of arterial hypertension. Since groups were not matched for each of the modifiable risk 
factors, conclusions made must be taken with caution. It can not be excluded that PAD was 
more severe in male patients, although disease severity was comparable, because more men 
than women had a prior LER before study entry. Morteover, prior LER was shown to be an 
independent risk factor for subsequent MI and ALI and both events independently increased 
mortality risk in EUCLID (42). Finally, the proportion of men with a history of surgical 
revascularization of any kind was higher before study entry, which might also suggest a more 





Female patients with PAD have a significantly reduced risk for MACE and all-cause 
mortality compared with men, while risk for MALE is similar for both sexes over a mean 
follow-up of 30 months. Sex-related differences are not explained by cardiovascular risk 
factor prevalence and medical interventions alone. Further investigation in defining additional 























 Competency in medical knowledge: Risk for Major Adverse Cardiovascular Events 
is higher for male than for female patients with symptomatic PAD. Equality in 
inclusion of both sexes in cardiovascular trials is an unmet need to improve 
recognition of sex-specific differences. 
 Translational outlook: Sex must be considered as a crucial factor for influencing the 
translation of basic research to clinical trials testing new therapies to inform clinical 
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Figure 1 (Central Figure). Kaplan-Meier curves for (A) major adverse cardiovascular 
events, (B) all-cause mortality, (C) major adverse limb events, and (D) post-randomization 
LER in female and male patients. 
Footnote: HR (95% CI) and p-values for the time from randomization to the first occurrence of the event is 
from a Cox proportional hazards model with a factor for sex (unadjusted analysis) and from a Cox proportional 
































































Age, yrs   <0.001  
median (25th, 75th) 66.0 (60.0, 72.0) 66.0 (60.0, 72.0)  66.0 (60.0, 73.0) 
 mean (±SD) 66.1 (8.2) 67.8 (8.9)   66.6 (8.4) 
Race, no. (%)   <0.001  
White 8176 (81.8) 3134 (80.6)  11,310 (81.5) 
Black or African American  293 (2.9) 276 (7.1)  569 (4.1) 
Asian 1294 (12.9) 340 (8.7)  1634 (11.8) 
Native Hawaiian or Pacific Islander 5 (<0.1) 0  5 (<0.1) 
American Indian or Alaska Native 65 (0.7) 60 (1.5)  125 (0.9) 
Other 164 (1.6) 78 (2.0)  242 (1.7) 
Weight, kg 79.9 (69.9, 90.0) 69.9 (60.0, 80.0) <0.001 76.5 (66.0, 88.0) 
Region   <0.001  
North America 1979 (19.8) 1066 (27.4)  3045 (21.9) 
Europe 5670 (56.7) 1828 (47.0)  7498 (54.0) 
Asia 1272 (12.7) 330 (8.5)  1602 (11.5) 
Central/South America 1076 (10.8) 664 (17.1)  1740 (12.5) 
Inclusion criteria   0.004  
Prior LER 5746 (57.5) 2129 (54.8)  7875 (56.7) 
ABI/TBI criteria 4251 (42.5) 1759 (45.2)  6010 (43.3) 
Rutherford classification for index limb at 
study entry 
  0.946  
Asymptomatic 1878 (18.8) 723 (18.6)  2601 (18.7) 
Mild/moderate claudication  5310 (53.1) 2100 (54.0)  7410 (53.4) 
Severe claudication 2335 (23.4) 893 (23.0)  3228 (23.3) 
Critical limb ischemia     














Minor tissue loss 152 (1.5) 55 (1.4)  207 (1.5) 
Major tissue loss 43 (0.4) 15 (0.4)  58 (0.4) 
Any prior amputation 746 (7.5) 220 (5.7) <0.001 966 (7.0) 
Prior major amputation above ankle 
(either limb) 
261 (2.6) 78 (2.0) 0.038 339 (2.4) 
History of only minor amputation 485 (4.9) 142 (3.7) 0.002 627 (4.5) 
Tobacco use   <0.001  
 Never smoked 1497 (15.0) 1487 (38.7)  2984 (21.6) 
 Current smoker 3284 (33.0) 1005 (26.1)  4289 (31.1) 
 Former smoker 5176 (52.0) 1354 (35.2)  6530 (47.3) 
Medical history†     
Stroke, TIA, carotid stenosis,  
or carotid revascularization 
4120 (41.2) 1388 (35.7) <0.001 5508 (39.7) 
MI, CAD, PCI, or CABG 3129 (31.3) 903 (23.2) <0.001 4032 (29.0) 
Diabetes mellitus 3774 (37.8) 1571 (40.4) 0.004 5345 (38.5) 
Hypertension 7705 (77.1) 3152 (81.1) <0.001 10,857 (78.2) 
Hyperlipidemia 7437 (74.4) 3043 (78.3) <0.001 10,480 (75.5) 
CKD‡ 2040 (21.1) 1292 (34.1) <0.001 3332 (24.7) 
Number of vascular beds   <0.001  
1 5440 (54.4) 2364 (60.8)  7804 (56.2) 
2 3479 (34.8) 1209 (31.1)  4688 (33.8) 
3 1078 (10.8) 315 (8.1)  1393 (10.0) 
Medications taken up to 30 days prior to 
randomization† 
    
Aspirin 6675 (66.8) 2596 (66.8) >0.999 9271 (66.8) 
Clopidogrel 3232 (32.3) 1241 (31.9) 0.642 4473 (32.2) 
DAPT 1609 (16.1) 658 (16.9) 0.235 2267 (16.3) 














ACE inhibitor and/or ARB 6337 (63.4) 2472 (63.6) 0.834 8809 (63.4) 
Laboratory parameters at baseline, median 
(25th, 75th) 
    
LDL-C, mmol/L 2.50 (1.90, 3.20) 2.60 (2.00, 3.40) <0.001 2.50 (1.90, 3.20) 
HDL-C, mmol/L 1.10 (1.00, 1.40) 1.30 (1.10, 1.60) <0.001 1.20 (1.00, 1.40) 
Total cholesterol, mmol/L 4.40 (3.70, 5.20) 4.70 (4.00, 5.60) <0.001 4.50 (3.80, 5.30) 
Hemoglobin A1C, % 6.40 (5.80, 7.50) 6.60 (5.90, 7.90) 0.583 6.40 (5.80, 7.60) 
eGFR, mL/min/1.73m2 77.6 (63.1, 92.9) 69.1 (54.3, 83.9) <0.001 75.0 (60.2, 90.6) 
 
Values are no. (%), unless otherwise indicated. 
*P-values for continuous variables are based on 2-sample t-tests; p-values for categorical variables are based on 
a chi-square tests (all cell sizes ≥5) or Fisher’s exact tests (at least one cell size <5). 
†Percentages for medical history and medications taken up to 30 days prior to randomization may add up to a 
value greater than 100%.  
‡Participants with a calculated eGFR<60 mL/min/1.73m2. 
ABI=ankle-brachial index; ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; 
CABG=coronary artery bypass grafting; CAD, coronary artery disease; CKD=chronic kidney disease; 
DAPT=dual antiplatelet therapy; eGFR=estimated glomerular filtration rate; HDL-C=high-density lipoprotein 
cholesterol; LDL-C=low-density lipoprotein cholesterol; LER=lower extremity revascularization; 
MI=myocardial infarction; PCI=percutaneous coronary intervention; SD=standard deviation; TBI=toe-brachial 

















Type of most recent revascularization procedure  
prior to randomization† 
   
Endovascular 3725 (65.0) 1532 (72.0) <0.001 
Surgical 2280 (39.8) 679 (31.9) <0.001 
Time since most recent revascularization procedure  






 >30 days to ≤6 months (180 days) 1854 (32.3) 679 (31.9) 0.703 
 >6 months (180 days) to ≤2 years (720 days) 1783 (31.1) 697 (32.7) 0.166 
 >2 years (720 days) 2095 (36.5) 753 (35.4) 0.333 
Location of most recent prior endovascular 
revascularization prior to randomization‡ 
   
Iliac 1266 (34.0) 469 (30.6) 0.004 
Common femoral artery 156 (4.2) 73 (4.8) 0.428 
Superficial femoral artery 1385 (37.2) 620 (40.5) 0.076 
Popliteal 208 (5.6) 121 (7.9) 0.003 
Tibial 323 (8.7) 117 (7.6) 0.153 
Type of most recent prior surgical revascularization  
prior to randomization§ 
   
Endarterectomy (CFA/SFA) 385 (16.9) 113 (16.6) 0.576 
Aorta-bifemoral bypass 420 (18.4) 100 (14.7) 0.107 
Axillary-femoral bypass 48 (2.1) 13 (1.9) 0.928 
Femoropopliteal bypass (above knee) 499 (21.9) 164 (24.2) 0.028 
Femoropopliteal bypass (below knee) 375 (16.4) 91 (13.4) 0.185 










Rutherford classification for index limb upon study 
entry 
   
Asymptomatic 1778 (31.0) 682 (32.0) 0.391 
Mild/moderate claudication 2666 (46.5) 993 (46.6) 0.923 
Severe claudication 1033 (18.0) 365 (17.1) 0.364 
Critical limb ischemia    
Rest pain 154 (2.7) 47 (2.2) 0.231 
Minor tissue loss 81 (14) 33 (1.6) 0.653 
Major tissue loss 19 (0.3) 9 (0.4) 0.546 
Previous amputation|| 474 145  
Above knee 103 (21.7) 34 (23.4) 0.663 
Below knee 356 (75.1) 109 (75.2) 0.987 
Ankle disarticulation 6 (1.3) 1 (0.7) >0.999 
Transtibial  69 (14.6) 20 (13.8) 0.819 
Partial foot  39 (8.2) 18 (12.4) 0.127 
Toe  254 (53.6) 76 (52.4) 0.804 
 
Values are no. (%). 
*P-values are based on a chi-square tests (all cell sizes ≥5) or Fisher’s exact tests (at least one cell size <5). 
†Most recent prior revascularization procedure is defined as the procedure which occurred closest to the date of 
randomization. Participants with both a surgical and endovascular procedure on the same closest date will be 
counted once for each procedure. 
‡Percentages are based on the number of patients whose most recent prior revascularization procedure was 
endovascular. Patients who report the same location in both limbs are counted only once for that location. 
Patients may report multiple locations for the procedure. 
§Percentages are based on the number of patients whose most recent prior revascularization procedure was 
surgical. Patients who report the same type in both limbs are counted only once for that type. Patients may report 
multiple types for the procedure. 
||Patients reporting multiple amputations prior to study entry are counted at most once for each amputation 
location. 















100 Pt-Yrs No. (%) 
 














MACE 1123 (11.2) 4.63 368 (9.5) 3.87 0.84 (0.74, 0.94) 0.003 0.77 (0.68, 0.88) <0.001 
CV death 539 (5.4) 2.14 167 (4.3) 1.70 0.80 (0.67, 0.95) 0.010 0.65 (0.54, 0.78) <0.001 
MI 508 (5.1) 2.08 175 (4.5) 1.83 0.88 (0.74, 1.04) 0.149 0.79 (0.66, 0.95) 0.014 
Ischemic stroke 223 (2.2) 0.90 77 (2.0) 0.80 0.88 (0.68, 1.14) 0.346 0.88 (0.67, 1.16) 0.351 
All-cause mortality 966 (9.7) 3.80 297 (7.6) 3.00 0.79 (0.69, 0.90) <0.001 0.61 (0.53, 0.71) <0.001 
MALE 296 (3.0) 1.20 103 (2.6) 1.07 0.89 (0.71, 1.12) 0.313 0.90 (0.71, 1.14) 0.369 
MALE plus post-
randomization LER 
1.362 (13.6) 5.91 522 (13.4) 5.81 0.99 (0.89, 1.09) 0.776 0.99 (0.88, 1.11) 0.839 
ALI requiring 
hospitalization 
170 (1.7) 0.69 62 (1.6) 0.64 0.94 (0.70, 1.25) 0.652 0.90 (0.66, 1.24) 0.536 
Major amputation 162 (1.6) 0.65 54 (1.4) 0.56 0.85 (0.63, 1.16) 0.312 0.81 (0.58, 1.12) 0.198 
Post-randomization LER 1.247 (12.5) 5.37 491 (12.6) 5.44 1.01 (0.91, 1.13) 0.784 1.02 (0.90, 1.14) 0.797 
TIMI major bleeding 169 (1.7) 0.78 53 (1.4) 0.65 0.83 (0.61, 1.13) 0.242 0.75 (0.55, 1.02) 0.069 
Intracranial bleeding 53 (0.5) 0.24 15 (0.4) 0.18 0.75 (0.42, 1.33) 0.329 0.72 (0.40, 1.28) 0.266 




No. (%) represents the raw number and percent of patients reporting at least 1 event. 
Event rate/100 patient-years is calculated as [(number of patients with event) / (sum of time at risk for event for all patients/360)]*100. 
The p-values and 95% CIs presented in this table have not been adjusted for multiplicity, and therefore inferences drawn from these p-values and 95% CIs may not be 
reproducible. 
ALI=acute limb ischemia; CI=confidence interval; CV=cardiovascular; HR=hazard ratio; LER=lower extremity revascularization; MACE=major adverse cardiovascular events; 



















HR (95% CI) 
p-value Interaction 
p-value 
n/Nsub (%) Event Rate/ 
100 Pt-Yrs 
n/Nsub (%) Event Rate/  
100 Pt-Yrs 
MACE <65 403/4471 (9.0) 3.65 85/1414 (6.0) 2.40 0.60 (0.47, 0.77) <0.001  
  ≥65  720/5526 (13.0) 5.45 283/2474 (11.4) 4.74 0.76 (0.65, 0.89) <0.001 0.111 
MALE  <65 145/4471 (3.2) 1.30 36/1414 (2.5) 1.01 0.86 (0.59, 1.25) 0.043  
  ≥65  151/5526 (2.7) 1.12 67/2474 (2.7) 1.10 0.93 (0.69, 1.26) 0.648 0.741 
 
Nsub=the number of patients in the given subgroup for that treatment group. 
Event rate/100 patient-years is calculated as [(number of patients with event) / (sum of time at risk for event for all patients/360)]*100. 
Time from randomization to the first occurrence of the event is compared between sex groups using an adjusted Cox proportional hazards model which contains factors for: 
Major Adverse Cardiovascular Event (MACE): sex, age group, an interaction term for sex*age group, baseline weight, tobacco use at baseline, region, number of prior vascular 
beds, Rutherford classification at baseline, history of any major amputations, history of only minor amputations, history of stroke, TIA, carotid stenosis, or carotid 
revascularization, history of diabetes, CKD at baseline (calculated eGFR <60 ml/min/1.73m 2), statin use up to 30 days prior to randomization, and Clopidogrel use up to 30 days 
prior to randomization, and for Major Adverse Limb Event (MALE):sex, age group, an interaction term for sex*age group, prior revascularization, baseline weight, Rutherford 
classification at baseline, history of any major amputations, history of only minor amputations, history of diabetes, statin use up to 30 days prior to randomization, and DAPT use 
up to 30 days prior to randomization. 
CI=confidence interval; HR=hazard ratio; MACE=major adverse cardiovascular event; MALE=major adverse limb event. 
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Figure 1. 
 
 
 
 
